Skip to main content
SpringerLink
Log in

TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer

  • original report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Lung cancer is the most common cause of cancer death worldwide, and its prognosis and treatment response rate as well as the survival rate remain poor. In our study, we performed next generation sequencing (NGS) with cancer panel (Illumina) for 19 Bulgarian patients with both non-small cell lung cancer (NSCLC; 18 patients) and neuroendocrine tumor (1 patient) and focused on common polymorphisms which define proven or reported sensitivity to platinum-based therapy. We report reference SNP (rs)1042522 (TP53), rs2228001 (XPC), rs2227983 (EGFR), rs1799793, and rs13181 (ERCC2) single nucleotide polymorphism variants which have been detected in our patients in homozygous and/or heterozygous state. Therefore, we give important information to confirm the role of those polymorphisms in tumor resistance and recurrence after chemotherapy treatment. The results reveal that TruSight Cancer Panel could be a useful clinical tool for determining pharmacogenetic variants associated with the effect of chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention. Compressed Mortality File 1999–2012, Series 20 No. 2R; 2014.

  2. Cancer Incidence in Bulgaria. 2012. Z. Valerianova, N. Dimitrova, S. Tonev, M. Vukov, p. 35.

  3. Sculier JP, Berghmans T, Meert AP. Advances in target therapy in lung cancer. Eur Respir Rev. 2015;24:23–9.

    Article  PubMed  Google Scholar 

  4. Joshi M, Rizvi SM, Belani CP. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag Res. 2015;7:75–82.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ai X, Shen S, Shen L, Lu S. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer. Biochimie. 2015;112:111–20.

    Article  CAS  PubMed  Google Scholar 

  6. Zimmermann S, Peters S. Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. Cancer Metastasis Rev. 2015:1–10.

  7. Rousseau B, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in non-small cell lung cancer treatment. Sci Rep. 2015;5. doi:10.1038/srep10356.

  8. Lampaki S, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. J Cancer. 2015;6(6):568–74.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Reck M, Von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–34.

    Article  CAS  PubMed  Google Scholar 

  10. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253–63.

    Article  CAS  PubMed  Google Scholar 

  11. Metzker ML. Sequencing technologies—the next generation. Nat Rev Genet. 2010;11(1):31–46.

    Article  CAS  PubMed  Google Scholar 

  12. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–96.

    Article  CAS  PubMed  Google Scholar 

  13. Kan Z, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869–73.

    Article  CAS  PubMed  Google Scholar 

  14. Wagle N, et al. Dissecting therapeutic resistance to RAF Inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tibaldi C, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797–803.

    Article  CAS  PubMed  Google Scholar 

  16. Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med. 2009;13(3):440–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dumont P, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.

    Article  CAS  PubMed  Google Scholar 

  18. Liu L, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6(11):1793–800.

    Article  PubMed  Google Scholar 

  19. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123:21–49.

    Article  Google Scholar 

  20. Ogle KS, Swanson GM, Woods N, et al. Cancer and comorbidity. Cancer. 2000;88:653–63.

    Article  CAS  PubMed  Google Scholar 

  21. Johnson N, et al. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet. 2007;16(9):1051–7.

    Article  CAS  PubMed  Google Scholar 

  22. Kim J, et al. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol. 2009;64(2):355–60.

    Article  CAS  PubMed  Google Scholar 

  23. Parmar S, et al. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J. 2013;13(2):181–8.

    Article  CAS  PubMed  Google Scholar 

  24. Liu W, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007;13(22 Pt 1):6788–95.

    Article  CAS  PubMed  Google Scholar 

  25. Sullivan I, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353(2):160–6.

    Article  CAS  PubMed  Google Scholar 

  26. Lu J, et al. Correlation of rs1799793 polymorphism in ERCC2 and the clinical response to platinum-based chemotherapy in patients with triple negative breast cancer. Int J Clin Exp Med. 2015;8(2):2934–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Boige V, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010;28(15):2556–64.

    Article  CAS  PubMed  Google Scholar 

  28. Giovannetti E, et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011;12(12):1641–52.

    Article  CAS  PubMed  Google Scholar 

  29. Wei S.-z., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Clinic, Specialized Hospital for Active Treatment in Oncology (National Center of Oncology), Sofia, Bulgaria

    N. Chilingirova &  G. Kurteva

  2. Department of Medical Genetics, Medical University of Sofia, Sofia, Bulgaria

    Z. Hammoudeh, D. Nikolova & D. Toncheva

  3. Genomic Laboratory, Hospital “Malinov”, Sofia, Bulgaria

    L. Balabanski, S. Ivanov, R. Vazharova & D. Toncheva

  4. Specialised Hospital for Active Treatment in Oncology (National Center of Oncology), Sofia, Bulgaria

    G. Kurteva

  5. Medical Oncology Clinic, Complex Oncology Center, Stara Zagora, Bulgaria

    P. Chilingirov

Authors
  1. N. Chilingirova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Hammoudeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Balabanski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ivanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Vazharova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Nikolova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Kurteva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Toncheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Chilingirov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Kurteva.

Additional information

N. Chilingirova, Z. Hammoudeh, G. Kurteva, D. Toncheva, P. Chilingirov equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chilingirova, N., Hammoudeh, Z., Balabanski, L. et al. TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer. memo 9, 30–38 (2016). https://doi.org/10.1007/s12254-015-0244-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-015-0244-2

Keywords

Search

Navigation